NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (CDT) (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced ...
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and ...
Conduit Pharmaceuticals (Nasdaq: CDT) has developed a unique business model to bring medicines to patients. Its novel approach addresses unmet medical needs by enhancing and extending the intellectual ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback